Ambrisentan

AMBRISENTAN

Manufacturer: Cipla USA Inc.

Score: 148.0

Quick Summary

Ambrisentan is an endothelin receptor antagonist used to treat pulmonary arterial hypertension (PAH). It improves exercise ability and delays clinical worsening. The drug has a high affinity for the ET-A receptor and is available in 5mg and 10mg film-coated tablets. Ambrisentan is contraindicated in pregnancy and idiopathic pulmonary fibrosis. The initial dose is 5mg once daily, which can be increased to 10mg as needed and tolerated. Special considerations are necessary for use in pregnancy, nursing mothers, pediatric patients, and geriatric patients.

Key Clinical Findings and Indications

Ambrisentan is used to treat pulmonary arterial hypertension (PAH)
Improves exercise ability and delays clinical worsening
High affinity for the ET-A receptor

Important Safety Information

Warning

May cause fetal harm if used during pregnancy

Contraindications

Pregnancy
Idiopathic pulmonary fibrosis

Adverse Reactions

Peripheral edema
Nasal congestion
Sinusitis
Flushing

Dosing Recommendations

General Guidance

Do not split, crush, or chew tablets

Pulmonary arterial hypertension (PAH)

Adult Dose

5mg once daily, increased to 10mg as needed and tolerated

Pediatric Dose

Special Population Considerations

Pregnancy

Contraindicated due to potential fetal harm
Females of reproductive potential must use acceptable methods of contraception

Nursing Mothers

It is not known whether ambrisentan is present in human milk
Decision should be made to discontinue breastfeeding or discontinue ambrisentan

Pediatric Use

Safety and effectiveness not established in pediatric patients
Juvenile animal data show decrease in brain weight

Geriatric Use

Elderly patients showed less improvement in walk distances
Peripheral edema more common in elderly patients